Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Berzosertib by Merck for Solid Tumor: Likelihood of Approval
Berzosertib is under clinical development by Merck and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Data Insights
Berzosertib by Merck for Neuroendocrine Cancer: Likelihood of Approval
Berzosertib is under clinical development by Merck and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase II...